24 September 2024

PRESS RELEASE
For Immediate Distribution

Vice President of AMPS, Dr. Duncan Syme, Calls for Thorough Investigation Into DNA Contamination in COVID-19 Vaccines

Dr. Duncan Syme, Vice President of the Australian Medical Professionals Society (AMPS), has today responded to findings from Canadian virologist Dr. David Speicher, released today by law firm PJ O'Brien & Associates, which confirm significant synthetic DNA contamination in Pfizer and Moderna COVID-19 vaccines distributed in Australia, including in children's vials.

AMPS has been raising concerns for several years regarding the safety of the COVID-19 vaccines, particularly those developed by Pfizer and Moderna. Dr. Speicher's findings, which show synthetic DNA levels up to 145 times above regulatory limits, further vindicate the Society's concerns. Specifically, the presence of the SV40 promoter in Pfizer vials, known to facilitate nuclear integration, presents a serious health risk to Australians.

> "This discovery confirms the legitimacy of AMPS' longstanding concerns about the safety and testing of these vaccines. We have been questioning the transparency and adequacy of regulatory oversight in Australia, particularly the rush to deploy these products without thorough safety evaluations," Dr. Syme said.
>
> "AMPS has always stood by its commitment to safeguard the health and well-being of Australians, and to protect healthcare professionals who voice legitimate concerns grounded in science."

The DNA contamination findings by Dr. Speicher and similar studies from Germany, Canada, and the United States indicate a broader, more serious issue with the safety profile of the Pfizer and Moderna vaccines. AMPS believes this is not an isolated incident but part of a systemic failure to ensure that these vaccines meet the required safety standards.

> "AMPS calls for an immediate and transparent investigation by the Department of Health and Aged Care into these findings. The contamination in the vaccines is well-documented, and the potential genomic risks must be assessed openly and without delay. We urge the government to listen to the evidence and act in the best interests of the public," AMPS Treasurer, Dr. Jeyanthi Kunadhasan added.

Dr. Speicher's report, alongside other eminent scientists who have reproduced these findings, highlights the urgent need for regulatory bodies to take these concerns seriously. AMPS demands that the Department of Health and Aged Care initiate a thorough and independent inquiry to reassess the continued use of these products in Australia, especially for vulnerable populations such as children and pregnant women.

Further information is contained in the Letter of Demand sent to the Australian Secretary of Health, Blair Comley, by lawyers PJ O'Brien & Associates today.

For further information, please contact:
Kara Thomas
Secretary
Email: kara.thomas@npaaservices.org.au